Company news from the 04/28/06 News Brief

Share this article:
Cytogen Corporation and Savient Pharmaceuticals reached a distribution agreement granting Cytogen exclusive marketing rights for Soltamox (tamoxifen citrate) in the US. Financial terms of the agreement were not disclosed. Soltamox, a cytostatic estrogen receptor antagonist, is the first oral liquid hormonal therapy approved in the US. It is indicated for the treatment of breast cancer in adjuvant and metastatic settings and to reduce the risk of breast cancer in women with ductal carcinoma in situ (DCIS) or with high risk of breast cancer.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.